Wednesday, September 17, 2014

*** Cost benefit analysis of the development and use of ante-mortem tests for transmissible spongiform encephalopathies ***

snip...

In summary, none of the respondents indicated that a live test for BSE was likely to be available in the immediate future. Nevertheless, it is known that at least three commercial companies that were not amongst the respondents are still interested in marketing a test for CJD in humans, and can legitimately be considered to have a real interest in the testing of bovines. This is no longer a priority for them however, and will probably not be progressed if they fail to gain approval for the testing of human blood.

snip...see full text ;

Wednesday, September 17, 2014

*** Cost benefit analysis of the development and use of ante-mortem tests for transmissible spongiform encephalopathies ***

http://transmissiblespongiformenceph...velopment.html


kind regards, terry